Literature DB >> 10874883

Flow cytometric detection of CD79a expression in T-cell acute lymphoblastic leukemias.

R Lai1, J Juco, S F Lee, S Nahirniak, W S Etches.   

Abstract

We evaluated the lineage specificity of CD79a in acute leukemias using 3-color flow cytometry in 58 consecutive cases. A panel of cell-surface antigens, including myeloid-associated markers, B-cell-associated markers, and T-cell-associated markers, was used. All cases of acute myeloid leukemia were CD79a-, whereas all cases of B-lineage acute lymphoblastic leukemia (ALL) were CD79a+. Three of 8 cases of T-cell ALL showed variable CD79a expression, indicating the presence of a blast subset expressing a relatively high level of CD79a. We investigated the clinical and pathologic characteristics of these 3 cases. All 3 cases had L1 or L2 morphology and expressed surface CD3. None of the other B-cell-associated markers were positive, although 1 case expressed CD13 and CD33. Uncommon random karyotypic abnormalities were identified in all 3 cases. Molecular studies demonstrated monoclonal gene rearrangement of T-cell receptor gamma in 2 of 3 cases. All 3 patients were 18 years old or younger; 1 patient did not enter remission, and 1 had disease relapse in 8 months. Our findings provide further support for the existence of a subset of T-cell ALL coexpressing CD3 and CD79a. Further study of the clinical and biologic significance of this subset may be warranted.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10874883     DOI: 10.1309/391R-93YF-DB4D-1L35

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  8 in total

1.  Flow cytometric analysis of de novo acute lymphoblastic leukemia in childhood: report from the Japanese Pediatric Leukemia/Lymphoma Study Group.

Authors:  Shotaro Iwamoto; Takao Deguchi; Hideaki Ohta; Nobutaka Kiyokawa; Masahito Tsurusawa; Tomomi Yamada; Kozo Takase; Junichiro Fujimoto; Ryoji Hanada; Hiroki Hori; Keizo Horibe; Yoshihiro Komada
Journal:  Int J Hematol       Date:  2011-07-30       Impact factor: 2.490

Review 2.  Nanomedicines in B cell-targeting therapies.

Authors:  Jiawei Wang; Jiyuan Yang; Jindřich Kopeček
Journal:  Acta Biomater       Date:  2021-10-21       Impact factor: 8.947

3.  Lupus Susceptibility Loci Predispose Mice to Clonal Lymphocytic Responses and Myeloid Expansion.

Authors:  Elliot H Akama-Garren; Michael C Carroll
Journal:  J Immunol       Date:  2022-04-27       Impact factor: 5.426

4.  Diagnosis of biphenotypic acute leukemia: a paradigmatic approach.

Authors:  Xianfeng Frank Zhao; Ivana Gojo; Teresa York; Yi Ning; Maria R Baer
Journal:  Int J Clin Exp Pathol       Date:  2009-10-10

5.  Correlation of expression of aberrant immunophenotypic markers in T-ALL with its morphology: A pilot study.

Authors:  Neha Garg; Mrinalini Kotru; Dilip Kumar; Rajesh Pathak; Meera Sikka
Journal:  J Lab Physicians       Date:  2018 Oct-Dec

Review 6.  The Genetic and Molecular Basis for Canine Models of Human Leukemia and Lymphoma.

Authors:  Anne C Avery
Journal:  Front Oncol       Date:  2020-01-24       Impact factor: 6.244

7.  Using digital RNA counting to establish flow cytometry diagnostic criteria for subtypes of CD34+ canine acute leukaemia.

Authors:  R Adam Harris; Emily D Rout; Janna A Yoshimoto; Paul R Avery; Anne C Avery
Journal:  Vet Comp Oncol       Date:  2022-05-23       Impact factor: 2.385

8.  Peripheral T-Cell Lymphoma with Aberrant Expression of CD19, CD20, and CD79a: Case Report and Literature Review.

Authors:  Rahul G Matnani; Rachel L Stewart; Joseph Pulliam; Chester D Jennings; Melissa Kesler
Journal:  Case Rep Hematol       Date:  2013-08-28
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.